Knappschaft Kliniken Saar GmbH
- Address
- lock Available on a paid plan
Ophthalmology
The Department of Ophthalmology at Knappschaft Kliniken Saar GmbH concentrates on cutting‑edge research in eye diseases, with a strong emphasis on age‑related macular degeneration, glaucoma, and retinal vascular conditions. Ongoing studies seek to enhance visual acuity by evaluating new drug delivery platforms, gene‑based approaches, and complement‑targeted therapies.
- Long‑acting anti‑VEGF agents for neovascular AMD
- Port Delivery System delivering sustained ranibizumab
- Gene therapy (RGX‑314) for neovascular macular disease
- Complement component inhibition for geographic atrophy
- Intraocular timolol‑releasing implants for primary open‑angle glaucoma
- Treatments for choroidal neovascularization secondary to pathologic myopia
The site is currently supporting 8 clinical trials with the expertise of 6 investigators, contributing valuable data from Sulzbach, Germany, that may soon translate into better preservation of sight for patients affected by macular degeneration, retinal edema, and glaucoma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Knappschaft Kliniken Saar GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ranibizumab | 3 | Unknown | 2021-10-22 | 2024-04-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.